Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Saad

Showing results (761-770 of 993) with videos related to

Pageof 100
Sort By:
Journal of Clinical Medicine|July 29, 2025
Perioperative Complications and In-Hospital Mortality After Radical Prostatectomy in Prostate Cancer Patients with a History of Heart Valve ReplacementNatali Rodriguez Peñaranda, Carolin Siech, Letizia Maria Ippolita Jannello, et al.
Urologic Oncology|February 7, 2026
Incremental dose-response effect of age on mortality in non-seminoma testis cancer patientsReha-Baris Incesu, Mattia Luca Piccinelli, Simone Morra, et al.
Urologic Oncology|June 29, 2025
Perioperative outcomes in testicular cancer patients treated with retroperitoneal lymph node dissectionLetizia Maria Ippolita Jannello, Andrea Baudo, Mario de Angelis, et al.
The Lancet. Oncology|April 3, 2025
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trialNobuaki Matsubara, Arun A Azad, Neeraj Agarwal, et al.
The Lancet. Oncology|April 3, 2025
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trialAndre P Fay, Karim Fizazi, Nobuaki Matsubara, et al.
Advances in Therapy|March 10, 2026
Treatment Patterns and Clinical Outcomes in Metastatic HR+/HER2- and Triple-Negative Breast Cancer in Canada: The HER2- TRENDS StudyKaren Gambaro, Kahina Rachedi, Mark Basik, et al.
Journal of Surgical Oncology|February 22, 2026
Does Laterality Affect the Risk of Intraoperative Complications in Adrenalectomy?Lukas Scheipner, Simone Morra, Andrea Baudo, et al.
Urologic Oncology|August 9, 2023
Conditional survival of stage III non-seminoma testis cancer patientsReha-Baris Incesu, Francesco Barletta, Stefano Tappero, et al.
European Journal of Cancer (Oxford, England : 1990)|June 30, 2026
Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trialKarim Fizazi, Matthew R Smith, Maha Hussain, et al.
European Urology|March 24, 2016
The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerChristopher P Evans, Celestia S Higano, Thomas Keane, et al.
Pageof 100

Showing results (761-770 of 993) with videos related to

Sort By:
Pageof 100
Journal of Clinical Medicine|July 29, 2025
Perioperative Complications and In-Hospital Mortality After Radical Prostatectomy in Prostate Cancer Patients with a History of Heart Valve ReplacementNatali Rodriguez Peñaranda, Carolin Siech, Letizia Maria Ippolita Jannello, et al.
Urologic Oncology|February 7, 2026
Incremental dose-response effect of age on mortality in non-seminoma testis cancer patientsReha-Baris Incesu, Mattia Luca Piccinelli, Simone Morra, et al.
Urologic Oncology|June 29, 2025
Perioperative outcomes in testicular cancer patients treated with retroperitoneal lymph node dissectionLetizia Maria Ippolita Jannello, Andrea Baudo, Mario de Angelis, et al.
The Lancet. Oncology|April 3, 2025
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trialNobuaki Matsubara, Arun A Azad, Neeraj Agarwal, et al.
The Lancet. Oncology|April 3, 2025
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trialAndre P Fay, Karim Fizazi, Nobuaki Matsubara, et al.
Advances in Therapy|March 10, 2026
Treatment Patterns and Clinical Outcomes in Metastatic HR+/HER2- and Triple-Negative Breast Cancer in Canada: The HER2- TRENDS StudyKaren Gambaro, Kahina Rachedi, Mark Basik, et al.
Journal of Surgical Oncology|February 22, 2026
Does Laterality Affect the Risk of Intraoperative Complications in Adrenalectomy?Lukas Scheipner, Simone Morra, Andrea Baudo, et al.
Urologic Oncology|August 9, 2023
Conditional survival of stage III non-seminoma testis cancer patientsReha-Baris Incesu, Francesco Barletta, Stefano Tappero, et al.
European Journal of Cancer (Oxford, England : 1990)|June 30, 2026
Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trialKarim Fizazi, Matthew R Smith, Maha Hussain, et al.
European Urology|March 24, 2016
The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerChristopher P Evans, Celestia S Higano, Thomas Keane, et al.
Pageof 100